Status:
COMPLETED
Differentiation HHD From HCM (EARLY-MYO-HHD)
Lead Sponsor:
RenJi Hospital
Collaborating Sponsors:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Ruijin Hospital
Conditions:
Hypertrophic Cardiomyopathy
Hypertensive Heart Disease
Eligibility:
All Genders
18-70 years
Brief Summary
Differentiating hypertrophic cardiomyopathy (HCM) from hypertensive heart disease (HHD) unavoidably encounters diagnostic challenges especially in patient of suspected HCM with history of hypertension...
Detailed Description
Both hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD) present left ventricular hypertrophy (LVH), but the prognosis varies. Nevertheless, the feasibility of distinguishing these ...
Eligibility Criteria
Inclusion
- Control group: (1) Absence of known systemic diseases; (2)Normal examinations（normal findings in both echocardiography and CMR）.
- Hypertrophic cardiomyopathy: 1) genetic determination of a pathogenic mutation or 2) left ventricular hypertrophy (LVH) (end-diastolic wall thickness \>15 mm) with resting left ventricular outflow tract obstruction or 3) hypertrophy in a recognizable pattern, i.e., ventricular bulge in apical-variant HCM; Of note, patients with documented HCM were divided into subgroups based on whether concomitant with hypertension or left ventricular outflow tract (LVOT) obstruction.
- Hypertensive Heart Disease: (1) Long durations of uncontrolled hypertension (systolic blood pressure≥150 mm Hg or diastolic blood pressure ≥90 mm Hg); Echocardiography: left ventricular wall thickness in diastolic \>11mm; Absence of other cardiac or systemic diseases; (2) left ventricular mass/body surface area \>115 g/m2 (Male) or \>95 g/m2 (Female).
Exclusion
- Documented coronary artery disease: previous history or CAG\>50%;
- NYHA Ⅳ level;
- Severe aortic valve stenosis;
- Standard metallic contraindications to CMR;
- Systemic diseases or Infiltrative cardiomyopathy;
- Septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
465 Patients enrolled
Trial Details
Trial ID
NCT03271385
Start Date
July 1 2017
End Date
December 31 2021
Last Update
November 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital
Shanghai, China, 200127